Elizabeth Douville

Nous sommes une organisation indépendante à but non lucratif créée pour mettre en œuvre le Centre de production de produits biologiques. Sur la base d’un mandat d’intérêt public, nous travaillons à mieux préparer le pays à de futures pandémies, à soutenir des projets d’intérêt public et à promouvoir la croissance de l’industrie canadienne des sciences de la vie. We are an independent not-for-profit corporation set up to operate the Biologics Manufacturing Centre. Based on a public-good mandate, our focus is pandemic preparedness, public-interest project support, and the overall growth of Canada’s life sciences industry.

Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes, more particularly USP15.

Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.

A Network of Centres of Excellence uniquely positioned to help Canada & the world accelerate the development of effective #immunotherapy for cancer treatment.

Nous sommes une organisation indépendante à but non lucratif créée pour mettre en œuvre le Centre de production de produits biologiques. Sur la base d’un mandat d’intérêt public, nous travaillons à mieux préparer le pays à de futures pandémies, à soutenir des projets d’intérêt public et à promouvoir la croissance de l’industrie canadienne des sciences de la vie. We are an independent not-for-profit corporation set up to operate the Biologics Manufacturing Centre. Based on a public-good mandate, our focus is pandemic preparedness, public-interest project support, and the overall growth of Canada’s life sciences industry.

Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.